Sarissa Capital Management LP Raises Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sarissa Capital Management LP boosted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 142.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,000 shares of the medical equipment provider's stock after purchasing an additional 37,000 shares during the quarter. Lantheus comprises approximately 1.7% of Sarissa Capital Management LP's portfolio, making the stock its 7th biggest holding. Sarissa Capital Management LP owned approximately 0.09% of Lantheus worth $5,636,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Assenagon Asset Management S.A. boosted its stake in Lantheus by 52.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 25,936 shares of the medical equipment provider's stock worth $2,320,000 after buying an additional 8,959 shares in the last quarter. Park Avenue Securities LLC raised its position in Lantheus by 26.4% in the 4th quarter. Park Avenue Securities LLC now owns 2,458 shares of the medical equipment provider's stock worth $220,000 after purchasing an additional 513 shares during the period. Empirical Asset Management LLC bought a new stake in Lantheus in the fourth quarter worth $323,000. Procyon Advisors LLC boosted its position in Lantheus by 11.1% during the fourth quarter. Procyon Advisors LLC now owns 3,613 shares of the medical equipment provider's stock valued at $323,000 after buying an additional 361 shares during the period. Finally, Shelton Wealth Management LLC grew its stake in shares of Lantheus by 77.8% during the fourth quarter. Shelton Wealth Management LLC now owns 11,969 shares of the medical equipment provider's stock valued at $1,071,000 after buying an additional 5,237 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Price Performance

NASDAQ LNTH traded down $0.26 during mid-day trading on Thursday, reaching $74.87. The stock had a trading volume of 574,813 shares, compared to its average volume of 983,941. The stock has a market cap of $5.18 billion, a PE ratio of 12.50 and a beta of 0.23. Lantheus Holdings, Inc. has a 1 year low of $73.18 and a 1 year high of $126.89. The company has a fifty day moving average price of $95.68 and a 200 day moving average price of $92.64.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same period last year, the business earned $1.69 earnings per share. The company's quarterly revenue was up .8% on a year-over-year basis. As a group, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on LNTH. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Truist Financial decreased their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, B. Riley lowered their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Lantheus presently has a consensus rating of "Buy" and a consensus target price of $132.67.

Insider Activity

In other news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This trade represents a 10.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock valued at $6,016,046 in the last 90 days. Company insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.